Abbott Laboratories (ABT) exhibits 56.4% gross margins and 11.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 18.4x enterprise multiple and 6.9% implied options volatility.
Sustained 56.4% gross profitability converts into 18.2% operating margin and 11.9% ROIC, outpacing sector cost of capital.
ROIC: 11.9% // GM: 56.4%YoY revenue trajectory of +5.7% paired with 4.09% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.7% // FCF YLD: 4.09%Altman Z-Score of 4.36 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.36 // F-SCORE: 8/9Trading at 27.7x trailing P/E (25.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 27.7x // EV/EBITDA: 18.4xOptions market prices a ±6.9% implied move with a 0.80 put/call ratio around $102.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.80Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 14.7% net margins.
NET MARGIN: 14.7% // D/E: 0.19x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ABT & activate live FRED threshold breach alerts.